Titan Pharmaceuticals (NASDAQ:TTNP) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNPFree Report) in a research note issued to investors on Monday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Titan Pharmaceuticals Stock Performance

Shares of NASDAQ TTNP opened at $6.94 on Monday. The business has a fifty day simple moving average of $6.79 and a 200 day simple moving average of $6.79. Titan Pharmaceuticals has a one year low of $5.00 and a one year high of $16.59.

Titan Pharmaceuticals (NASDAQ:TTNPGet Free Report) last issued its earnings results on Wednesday, May 15th. The specialty pharmaceutical company reported ($1.24) EPS for the quarter. Titan Pharmaceuticals had a negative net margin of 2,014.71% and a negative return on equity of 99.96%.

About Titan Pharmaceuticals

(Get Free Report)

Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.

Featured Stories

Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.